Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis - Okura, Y; Namisaki, T; Moriya, K (Hepatol Res, 2017)
et al.